Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with …
Immunotherapy has been incorporated into the first-and second-line treatment strategies for
non-small cell lung cancer (NSCLC), profoundly ushering in a new treatment landscape …
non-small cell lung cancer (NSCLC), profoundly ushering in a new treatment landscape …
Combining radiotherapy and immunotherapy in lung cancer: can we expect limitations due to altered normal tissue toxicity?
F Wirsdörfer, S De Leve, V Jendrossek - International journal of molecular …, 2018 - mdpi.com
In recent decades, technical advances in surgery and radiotherapy, as well as
breakthroughs in the knowledge on cancer biology, have helped to substantially improve the …
breakthroughs in the knowledge on cancer biology, have helped to substantially improve the …
EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies
Y Jia, X Li, T Jiang, S Zhao, C Zhao… - … Journal of Cancer, 2019 - Wiley Online Library
Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD‐
1/PD‐L1) pathway have profoundly improved the clinical management of non‐small‐cell …
1/PD‐L1) pathway have profoundly improved the clinical management of non‐small‐cell …
Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2
N Bora-Singhal, D Mohankumar, B Saha, CM Colin… - Scientific reports, 2020 - nature.com
Non-small cell lung cancer (NSCLC) is known to have poor patient outcomes due to
development of resistance to chemotherapy agents and the EGFR inhibitors, which results in …
development of resistance to chemotherapy agents and the EGFR inhibitors, which results in …
[HTML][HTML] Homologous recombination repair deficiency and the immune response in breast cancer: a literature review
The success of cancer immunotherapy with immune checkpoint blockade (ICB) has
demonstrated the importance of targeting a preexisting immune response in a broad …
demonstrated the importance of targeting a preexisting immune response in a broad …
COVID-19 and coagulative axis: review of emerging aspects in a novel disease
M Boccia, L Aronne, B Celia, G Mazzeo… - … Archives for Chest …, 2020 - monaldi-archives.org
Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is
commonly complicated with coagulopathy and that disseminated intravascular coagulation …
commonly complicated with coagulopathy and that disseminated intravascular coagulation …
[HTML][HTML] Functional gene knockout of NRF2 increases chemosensitivity of human lung cancer A549 cells in vitro and in a xenograft mouse model
Recent studies point to the evolution of drug resistance in lung cancer as being centered, at
least in part, on the upregulation of various genes involved in controlling efflux or drug …
least in part, on the upregulation of various genes involved in controlling efflux or drug …
Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer
A Bianco, F Perrotta, G Barra, U Malapelle… - International Journal of …, 2019 - mdpi.com
Manipulation of the immune response is a game changer in lung cancer treatment,
revolutionizing management. PD1 and CTLA4 are dynamically expressed on different T cell …
revolutionizing management. PD1 and CTLA4 are dynamically expressed on different T cell …
TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma
L Liang, H He, S Jiang, Y Liu, J Huang, X Sun… - International Journal of …, 2022 - mdpi.com
Background: Osimertinib-based therapy effectively improves the prognosis of lung
adenocarcinoma (LUAD) patients with epidermal growth factor receptor mutations. However …
adenocarcinoma (LUAD) patients with epidermal growth factor receptor mutations. However …
Current clinical progress of PD-1/PD-L1 immunotherapy and potential combination treatment in non–small cell lung cancer
JX Li, JM Huang, ZB Jiang, RZ Li… - Integrative Cancer …, 2019 - journals.sagepub.com
Conventional methods in treating non–small cell lung cancer contain surgery,
chemotherapy, radiotherapy, and targeted therapy, which have various defects. Recently …
chemotherapy, radiotherapy, and targeted therapy, which have various defects. Recently …